VERU INC. DL-01
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includ… Read more
VERU INC. DL-01 (FMW) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, VERU INC. DL-01 (FMW) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
VERU INC. DL-01 - Net Assets Trend (None–None)
This chart illustrates how VERU INC. DL-01's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for VERU INC. DL-01 (None–None)
The table below shows the annual net assets of VERU INC. DL-01 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to VERU INC. DL-01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
VERU INC. DL-01 Competitors by Market Cap
The table below lists competitors of VERU INC. DL-01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Christina Lake Cannabis Corp
OTCQB:CLCFF
|
$5.18 Million |
|
Nation Group (Thailand) PCL
BK:NATION
|
$5.18 Million |
|
K. W. Metal Work Public Company Limited
BK:KWM
|
$5.18 Million |
|
Turism Hotelur
RO:EFO
|
$5.18 Million |
|
Altima Resources Ltd
PINK:ARSLF
|
$5.18 Million |
|
Nutriband Inc. Warrant
NASDAQ:NTRBW
|
$5.18 Million |
|
Lease IT Public Company Limited
BK:LIT
|
$5.17 Million |
|
Pontiac Bancorp Inc
PINK:PONT
|
$5.17 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in VERU INC. DL-01's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares VERU INC. DL-01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently VERU INC. DL-01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares VERU INC. DL-01's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| VERU INC. DL-01 (FMW) | €- | N/A | N/A | $5.18 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |